Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold sold shares of the company's common stock on March 7th and March 10th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock on March 7th and March 10th, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 11, 2024.
• On March 7th, shares were sold at a weighted average price of $20.052 and $20.744.
• On March 10th, shares were sold at a weighted average price of $19.518.
• The transactions involved both direct holdings and indirect holdings through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• Following the reported transactions, Maetzold continues to hold a significant number of shares directly and indirectly through these trusts.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects.

Risks

• The market may react negatively to insider selling, even if it's under a pre-arranged plan.
• Continued sales by the CEO could put downward pressure on the stock price.

Industry Context

Insider selling is a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. However, the market often scrutinizes such sales for potential implications about the company's future prospects.

Stakeholder Impact

• Shareholders may be concerned about the CEO selling shares, even under a pre-arranged plan.
• The sales could create downward pressure on the stock price, affecting shareholder value.

Key Dates